Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With HR+/HER2- Metastatic Breast Cancer Who Have Received Endocrine Therapy

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2023
This article has no abstract
Epistemonikos ID: eae8d614ec727de30ff7e0a03146c52e83b1600f
First added on: Apr 11, 2025